Quinolones | Market Size, Share & Growth Report 2025-2033

    The Quinolones Market Report is Segmented by Product Type (Ciprofloxacin, Levofloxacin, Moxifloxacin, Ofloxacin, and Norfloxacin), Application (Respiratory Infections, Urinary Tract Infections, Skin Infections, Sexually Transmitted Infections, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores, and Others), Ingredient Type (Fluoroquinolones, Non-fluorinated Quinolones, Third-generation Quinolones, Fourth-generation Quinolones, and Others).

    Base Year: 20255 RegionsForecast 2025–2033185 Pages
    Market Size (2025)
    USD 5.03 billion
    CAGR
    4.20%
    Forecast Value (2033)
    USD 6.99 billion

    Quinolones Market

    4.20% CAGR

    Market Size & Share

    2025 to 2033 forecast analysis

    Market Size (2025)
    USD 5.03 billion
    CAGR
    4.20%
    (2025–2033)
    Forecast (2033)
    USD 6.99 billion

    Key Findings

    Market reaches USD 6.99 billion by 2033

    The global quinolones market was estimated at approximately USD 5.03 billion in 2025 and is projected to reach around USD 6.99 billion by 2033, a CAGR of approximately 4.20% during 2025-2033, based on Core Market Research estimates. Three independent firms place the fluoroquinolone market, which is effectively the whole commercial class, at USD 4.83 to 4.91 billion for 2025.

    Generic suppliers hold the volume

    No company holds a branded position in the molecules that carry almost all prescribing, since ciprofloxacin has been generic since 2004 and branded levofloxacin was discontinued in December 2017. Competition runs on manufacturing cost and regulatory filing coverage rather than on clinical differentiation.

    Oral bioavailability keeps the class in use

    Fluoroquinolones combine broad Gram-negative activity with oral absorption close to intravenous levels, which allows a patient to complete treatment for complicated urinary and intra-abdominal infection outside hospital. No equally convenient oral alternative exists for several of those indications.

    Three boxed warnings have cut prescribing

    The Food and Drug Administration added boxed warnings in 2008, 2016 and December 2018, covering tendon rupture, disabling and potentially permanent effects, and aortic aneurysm rupture. Ambulatory use in the United States fell approximately 27 percent between 2015 and 2019 as a result.

    Ciprofloxacin carries the largest volume

    Ciprofloxacin has been generic in the United States since 2004 and remains the most widely stocked agent in the class for urinary and gastrointestinal indications. All five product types named in this market are fluoroquinolones, so the non-fluorinated quinolones that gave the class its name are now commercially negligible.

    North America holds the largest revenue share

    North America accounted for approximately 46.2 percent of the global fluoroquinolone market in 2025, the largest regional share, despite applying some of the most severe prescribing restrictions. The position reflects generic antibiotic pricing above that in other markets rather than greater usage.

    Market Analysis

    How the market stands today, and what is shaping it

    The global quinolones market was estimated at approximately USD 5.03 billion in 2025 and is projected to reach around USD 6.99 billion by 2033, representing a CAGR of approximately 4.20% during 2025-2033, based on Core Market Research estimates. The market consists almost entirely of fluoroquinolones, principally generic ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin and norfloxacin, together with delafloxacin, the one agent still under brand protection. Growth rests on oral bioavailability close to intravenous levels that lets patients complete therapy outside hospital, on delafloxacin's activity against meticillin-resistant Staphylococcus aureus, and on generic pricing that keeps the class affordable across Asia, Africa and Latin America. Expansion is constrained by three United States boxed warnings added in 2008, 2016 and 2018, by European Medicines Agency restrictions imposed in 2019, and by resistance that has closed gonorrhoea and enteric fever indications. Competition is generic competition among Teva Pharmaceutical Industries Ltd., Cipla Limited, Hikma Pharmaceuticals PLC and Aurobindo Pharma Limited, with CorMedix Inc. holding the one differentiated asset. CorMedix's acquisition of Melinta Therapeutics on 2 September 2025 is the clearest current signal of where commercial attention now sits.

    Market Dynamics

    Key market dynamics and their impact on the industry landscape

    Market Drivers

    • Fluoroquinolones retain broad Gram-negative activity with oral bioavailability close to intravenous, which allows a patient to complete therapy outside hospital. That property is why ciprofloxacin and levofloxacin remain stocked for complicated urinary and intra-abdominal infection despite three boxed warnings covering tendon rupture, aortic dissection and central nervous system effects.
    • Delafloxacin extended the class chemically by adding an anionic character that improves activity at the acidic pH found in infected tissue, and it covers meticillin-resistant Staphylococcus aureus, which earlier fluoroquinolones do not. The Food and Drug Administration approved it in 2017 for skin infection and subsequently for community-acquired bacterial pneumonia.
    • Regulators have restricted rather than removed the class, which preserves the indications where no equivalent oral alternative exists. The 2016 Food and Drug Administration advisory addressed uncomplicated sinusitis, bronchitis and urinary tract infection specifically, leaving complicated and resistant infections within approved use.
    • Ciprofloxacin has been generic in the United States since 2004 and levofloxacin since the Levaquin discontinuation in December 2017, so acquisition cost is a few cents per tablet. That price makes the class payable in public health systems and in retail channels across Asia, Africa and Latin America where branded alternatives are unaffordable.
    • CorMedix acquired Melinta Therapeutics on 2 September 2025, taking the Baxdela delafloxacin franchise. Commercial activity in this class now concentrates on the one agent still under brand protection rather than on the generic molecules that carry the volume.

    Market Challenges

    • The class carries three separate boxed warnings in the United States, added in 2008 for tendinitis and tendon rupture, in 2016 for disabling and potentially permanent effects, and in December 2018 for aortic aneurysm rupture and dissection. No other widely used oral antibiotic class carries a comparable accumulation of regulatory warnings.
    • Prescribing has fallen measurably rather than stabilised. Ambulatory fluoroquinolone use in the United States declined approximately 27 percent between 2015 and 2019, and outpatient prescription fills fell most sharply in association with the May 2016 Food and Drug Administration advisories.
    • The European Medicines Agency's Article 31 referral led to suspension of marketing authorisations for some quinolone products and restriction of the remainder in 2019. National agencies have issued repeated reminders since, including a Pharmacovigilance Risk Assessment Committee review in May 2023, which indicates that prescribing has not fully aligned with the restrictions.
    • Resistance has removed indications the class once held. Neisseria gonorrhoeae resistance moved sexually transmitted infection treatment to ceftriaxone-based regimens, and fluoroquinolone-resistant Salmonella Typhi is now widespread across South Asia, which eliminated a first-line enteric fever use.
    • Generic status leaves no commercial sponsor to defend the class. With ciprofloxacin generic since 2004 and branded levofloxacin discontinued in December 2017, no company holds the margin that would fund post-marketing studies or physician education to position the remaining appropriate uses.

    Opportunities

    • Delafloxacin covers meticillin-resistant Staphylococcus aureus, which earlier fluoroquinolones do not, and it holds both skin infection and community-acquired pneumonia indications. Its position under CorMedix ownership since September 2025 could support a narrower but defensible commercial niche than the generic molecules allow.
    • Asia Pacific is forecast to grow at approximately 8.5 percent annually, faster than any other region. Manufacturers already producing ciprofloxacin and levofloxacin in India, including Cipla Limited and Aurobindo Pharma Limited, may capture that growth from existing capacity rather than through new investment.
    • Topical and otic ofloxacin formulations fall outside the systemic restrictions the Food and Drug Administration and European Medicines Agency applied, because the adverse effects that drove those actions relate to systemic exposure. Reformulation towards local delivery could preserve uses the systemic warnings have closed.
    • Stewardship programmes have reduced fluoroquinolone use substantially, but the class retains approved indications in complicated infection. Diagnostic tools that identify when a fluoroquinolone remains the appropriate choice could recover appropriate prescribing that broad restriction has suppressed alongside inappropriate prescribing.

    Segment Analysis

    Market segmentation by product type, application, distribution channel, ingredient type

    Ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin and norfloxacin are all fluoroquinolones, so this product set does not span the wider quinolone class it sits within. Ciprofloxacin carries the largest volume, having been generic in the United States since 2004, and it remains the agent most widely stocked for urinary and gastrointestinal indications. Levofloxacin lost its branded supply when Janssen discontinued Levaquin in December 2017 and is now entirely generic. Moxifloxacin holds respiratory indications where its activity against atypical organisms matters. Norfloxacin has largely fallen out of use in Europe following the Article 31 referral, and ofloxacin now appears more often in otic and ophthalmic formulations than in systemic therapy.

    Geography Analysis

    Regional market analysis

    Largest Market
    North America
    Fastest Growing
    Asia Pacific

    North America

    North America accounted for approximately 46.2% of the global fluoroquinolone market in 2025, the largest regional share, despite being the region where regulatory restriction has been most severe. The explanation is price rather than volume, since United States pricing for generic antibiotics remains above that in most other markets. Ambulatory fluoroquinolone use in the United States fell approximately 27 percent between 2015 and 2019, and outpatient prescription fills declined most strongly in association with the May 2016 Food and Drug Administration warnings. The region is also where delafloxacin was approved in 2017 and where its franchise now sits with CorMedix.

    Europe

    Europe applies the most restrictive regulatory position on this class of any region. The European Medicines Agency completed an Article 31 referral and recommended in 2019 that systemic and inhaled fluoroquinolones be restricted, with marketing authorisations suspended for some quinolone products entirely. National agencies including AIFA in Italy and the HPRA in Ireland have issued repeated reminders of those restrictions, and the Pharmacovigilance Risk Assessment Committee returned to the subject in May 2023. Published analysis of post-referral prescribing found the label changes altered dispensing patterns across European Union member states.

    Asia Pacific

    Asia Pacific is expected to grow at the fastest compound annual growth rate in this market, at approximately 8.5 percent, well above the global rate. Three factors separate the region from North America and Europe: antibiotic prescribing restrictions are applied less uniformly, over-the-counter availability persists in several countries despite prescription-only rules, and the generic manufacturing base is located there. Cipla Limited and Aurobindo Pharma Limited both manufacture ciprofloxacin and levofloxacin from Indian facilities, supplying domestic demand and exporting to regulated markets. Rising antimicrobial resistance in the region also sustains demand for broad-spectrum oral agents.

    Latin America

    Latin American quinolone use is shaped by the gap between prescription-only regulation and actual dispensing practice, with ciprofloxacin widely available in retail pharmacies across the region. Brazil and Mexico are the largest national markets, supplied predominantly by local and Indian generic manufacturers rather than by originator companies. No government statistical agency in the region publishes quinolone-specific revenue data that would support a regional market figure, so the position described here rests on documented dispensing practice and manufacturing supply rather than on measured market value.

    Middle East & Africa

    Hikma Pharmaceuticals PLC originated in Jordan and retains substantial regional manufacturing, which places generic quinolone supply inside the region rather than requiring import. Gastrointestinal and urinary infection burden sustains ciprofloxacin demand across North Africa and the Middle East at rates above those now seen in Europe. Enteric fever presents a specific constraint, because fluoroquinolone resistance in Salmonella Typhi has become widespread in South Asia and parts of Africa, which has removed the class from first-line use for an indication it once dominated. No regional market revenue series for quinolones was identified from any statistical agency.

    Competitive Landscape

    Key players and market positioning analysis

    Competition in quinolones is generic competition, and the question it turns on is manufacturing cost and regulatory filing coverage rather than clinical differentiation. Ciprofloxacin has been generic in the United States since 2004 and levofloxacin since Janssen discontinued branded Levaquin in December 2017, so the molecules that carry almost all volume are supplied by companies that did not discover them. Teva Pharmaceutical Industries Ltd. is the largest of those suppliers by breadth of portfolio, carrying both ciprofloxacin and levofloxacin presentations across multiple regulated markets. Cipla Limited and Aurobindo Pharma Limited manufacture the same molecules from Indian facilities, supplying domestic demand and exporting into the United States and Europe, and their cost position is what sets the price other suppliers have to meet. Hikma Pharmaceuticals PLC occupies a distinctive position, having originated in Jordan and retained manufacturing across the Middle East and North Africa alongside its United States generic injectables business, which places it on both sides of the regulated and emerging market divide. CorMedix Inc. competes on entirely different terms, having acquired Melinta Therapeutics on 2 September 2025 and with it the Baxdela delafloxacin franchise, the one agent in the class still differentiated by patent and by activity against meticillin-resistant Staphylococcus aureus. Bayer, which discovered ciprofloxacin and moxifloxacin, and Johnson & Johnson, whose Janssen subsidiary developed and then discontinued Levaquin, shaped the class but no longer define its commercial structure. The feature that shapes the class most is that regulatory restriction has fallen on molecules with no branded sponsor, so there is no company with both the margin and the incentive to establish where fluoroquinolones remain the right choice.

    5 companies profiled in this report

    Major Players

    Leading companies in the market

    T
    Teva Pharmaceutical Industries Ltd.
    Israel
    C
    Cipla Limited
    India
    H
    Hikma Pharmaceuticals PLC
    United Kingdom
    A
    Aurobindo Pharma Limited
    India
    C
    CorMedix Inc.
    United States

    Industry Developments

    8 recorded developments

    2025

    CorMedix acquired Melinta Therapeutics on 2 September 2025, taking ownership of the Baxdela delafloxacin franchise. The transaction placed the class's newest approved agent inside a company whose principal business is in anti-infective and dialysis-related products rather than broad antibacterial supply.

    2021

    Published analysis recorded a decline of approximately 27 percent in ambulatory fluoroquinolone use in the United States between 2015 and 2019, with outpatient prescription fills falling most strongly in association with the May 2016 Food and Drug Administration warnings. The regulatory actions produced a measurable and sustained volume reduction rather than a temporary one.

    2019

    The European Medicines Agency completed an Article 31 referral begun in 2018 and recommended substantial restrictions on systemic and inhaled fluoroquinolones across the European Union, including suspension of marketing authorisations for some quinolone products. The review addressed long-lasting, disabling and potentially irreversible musculoskeletal and nervous system reactions.

    2018

    The Food and Drug Administration warned in December 2018 that fluoroquinolones increase the occurrence of aortic aneurysm rupture and aortic dissection, and added that finding to the boxed warning. The agency advised against use in patients with existing aortic disease or at elevated risk of it.

    2017

    The Food and Drug Administration approved delafloxacin, marketed as Baxdela, for acute bacterial skin and skin structure infections. It was the first new fluoroquinolone approved in the United States in more than a decade, and it entered a class already carrying three boxed warnings.

    2017

    Janssen, the Johnson & Johnson subsidiary, discontinued production of Levaquin in December 2017 as concerns over fluoroquinolone adverse effects grew. The withdrawal of the branded levofloxacin product left the molecule to generic suppliers while demand was already contracting.

    2016

    The Food and Drug Administration issued a boxed warning in 2016 covering disabling and potentially permanent adverse effects of systemic fluoroquinolones, and advised against their use in uncomplicated urinary tract infection, sinusitis and bronchitis where alternatives exist. Advisories released in May and July 2016 were each associated with statistically significant decreases in prescribing.

    2008

    The United States Food and Drug Administration added a boxed warning to systemic fluoroquinolones covering tendinitis and tendon rupture. It was the first of a sequence of safety actions that progressively narrowed the indications in which the class could be prescribed.

    Table of Contents

    13 comprehensive chapters

    1. Introduction

    1.1 Market Definition

    1.2 Scope of the Study

    1.3 Research Objectives

    2. Research Methodology

    2.1 Research Approach

    2.2 Data Sources

    2.3 Market Estimation Approach

    2.4 Forecast Assumptions

    2.5 Research Limitations

    3. Executive Summary and Market Overview

    3.1 Market Overview

    3.2 Market Size and Forecast

    3.3 Key Findings

    3.4 Market Structure

    4. Market Dynamics

    4.1 Market Drivers

    4.2 Market Challenges

    4.3 Market Opportunities

    4.4 Market Trends and Insights

    5. Market Segmentation Analysis

    5.1 Market Segmentation Overview

    5.2 By Product Type

    5.3 By Application

    5.4 By Distribution Channel

    5.5 By Ingredient Type

    6. Geographic Analysis

    6.1 North America

    6.2 Europe

    6.3 Asia Pacific

    6.4 Latin America

    6.5 Middle East & Africa

    6.6 Regional Market Comparison

    7. Industry Analysis and Developments

    7.1 Industry Developments

    7.2 Industry Timeline

    8. Competitive Landscape

    8.1 Market Structure and Competitive Positioning

    8.2 Major Players

    8.3 Strategic Developments

    8.4 Key Competitive Factors

    9. Key Player Profiles

    9.1 Teva Pharmaceutical Industries Ltd.

    9.2 Cipla Limited

    9.3 Hikma Pharmaceuticals PLC

    9.4 Aurobindo Pharma Limited

    9.5 CorMedix Inc.

    10. Market Outlook and Forecast

    10.1 Market Size and Growth Outlook

    10.2 Regional Market Outlook

    10.3 Future Market Trends

    10.4 Key Risks to the Forecast

    11. Strategic Insights and Market Opportunities

    11.1 Growth Opportunities

    11.2 Key Risks and Constraints

    11.3 Strategic Considerations

    12. Frequently Asked Questions
    13. Appendix and Research References

    13.1 Glossary of Terms

    13.2 Abbreviations

    13.3 Research References

    Scope of the Report

    Report coverage and methodology

    Study Period

    Base Year: 2025
    Forecast Period: 2025 - 2033

    Geographic Scope

    North America, Europe, Asia Pacific, Latin America, Middle East & Africa

    Companies Covered

    Teva Pharmaceutical Industries Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Aurobindo Pharma Limited + more

    Data Sources

    Primary research, industry interviews, regulatory filings, company reports

    Frequently Asked Questions

    Common questions about this report

    The market was estimated at approximately USD 5.03 billion in 2025, based on Core Market Research estimates. The figure rests on three independent estimates placing the fluoroquinolone market at USD 4.83 billion, USD 4.89 billion and USD 4.91 billion for 2025, with a small addition for non-fluorinated quinolones that remain in limited use.

    Ready to Get the Full Report?

    Access comprehensive market insights, detailed analysis, and strategic recommendations to make informed business decisions.

    Single User
    $3,000
    Multi User
    $4,800
    Enterprise
    $6,600